Capital Fund Management (CFM)
AMAG

Capital Fund Management (CFM)’s AMAG Pharmaceuticals AMAG Stock Holding History

Capital Fund Management (CFM)’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-19,900
Closed -$199K – 1991
2019
Q2 		$199K Buy
+19,900
New +$215K ﹤0.01% 1531
2017
Q2 		– Sell
-113,703
Closed -$2.56M – 1823
2017
Q1 		$2.56M Buy
113,703
+44,961
+65% +$1.08M 0.02% 666
2016
Q4 		$2.39M Buy
68,742
+42,400
+161% +$1.27M 0.02% 712
2016
Q3 		$646K Buy
26,342
+5,609
+27% +$140K 0.01% 1111
2016
Q2 		$496K Buy
20,733
+1,622
+8% +$37.2K ﹤0.01% 1175
2016
Q1 		$447K Buy
19,111
+2,811
+17% +$66.7K ﹤0.01% 1196
2015
Q4 		$492K Buy
+16,300
New +$527K 0.01% 1129
2014
Q3 		– Sell
-11,975
Closed -$248K – 1918
2014
Q2 		$248K Buy
+11,975
New +$221K ﹤0.01% 1504

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Fund Management (CFM)'s AMAG Position: Q3 2019 in Review

Capital Fund Management (CFM) sold out of AMAG Pharmaceuticals (AMAG) in Q3 2019, closing a stake of 19,900 shares — an estimated $199K sold.

Capital Fund Management (CFM) first reported a position in AMAG in Q2 2014 and held it in 8 quarters. The position peaked at $2.56M in Q1 2017. 156 funds tracked by Wall St. Rank hold AMAG as of Q3 2019.

  • Capital Fund Management (CFM) reported no remaining AMAG Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 19,900 AMAG Pharmaceuticals shares in Q3 2019, an estimated $199K.
  • Capital Fund Management (CFM) first reported a position in AMAG Pharmaceuticals in Q2 2014 and held it in 8 quarters.
  • Capital Fund Management (CFM)'s AMAG Pharmaceuticals position peaked at $2.56M in Q1 2017.
  • 156 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2019.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2019, filed 13 Nov 2019.